Source: Blessed CBD.
  • High Tide (HITI) subsidiary Blessed CBD has initiated sales on Amazon U.K.
  • Products include gummies, capsules and balms with additional listings forthcoming in the next few days
  • The placement is in line with the company’s international expansion plans to solidify its distribution and market presence
  • High Tide is Canada’s largest retailer of recreational cannabis measured by revenue
  • High Tide (HITI) is down by 6.27 per cent trading at $2.84 per share

High Tide (HITI) subsidiary Blessed CBD has initiated sales on Amazon U.K.

Products include gummies, capsules and balms with additional listings forthcoming in the next few days.

The placement follows thorough compliance checks from Amazon and Blessed’s reception of a Novel Foods Authorization from the U.K.’s Food Standards Agency.

High Tide intends to continue strategic international expansion through new markets and distribution channels leveraging its expanding brand portfolio.

“Amazon is unmatched as a global online marketplace, and by joining their platform in the U.K., we are broadening Blessed’s reach and making our products accessible for many more consumers,” said Raj Grover, President and CEO of High Tide. “Today’s announcement is another example of the strength of High Tide’s diversified international cannabis ecosystem, as we are able to keep growing our presence and customer bases even in jurisdictions where cannabis is not yet legal.”

High Tide is a retail-focused cannabis company with brick-and-mortar as well as global e-commerce assets. The company is Canada’s largest retailer of recreational cannabis measured by revenue.

High Tide (HITI) is down by 6.27 per cent trading at $2.84 per share as of 12:58 pm EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.